Greenwich LifeSciences reported cash from operations of -$4.70M and free cash flow of -$4.70M for the quarter ended Mar 2026, down 156.3% year over year. This cash flow statement covers 27 quarters of results from Sep 2019 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow StatementCash Flow | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||
| Net Income | -0.75M | -0.86M | -2.36M | -1.97M | -0.75M | -2.32M | -2.79M | -2.12M | -1.63M | -2.39M | -2.75M | -2.47M | -2.61M | -2.67M | -9.67M | -2.74M | -3.75M | -3.71M | -9.15M | -5.66M | |||||||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||||||||
| Amortizatization of IntangiblesAmort. of Intangibles | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 876.00 | ||||||||||
| Share-based CompensationStock Comp. | 0.17M | 0.17M | 0.17M | 0.17M | 0.22M | 0.76M | 0.59M | 1.84M | 0.59M | -0.65M | 0.59M | 0.59M | 0.59M | 0.59M | 5.47M | 1.54M | 1.54M | 1.54M | 2.17M | 1.54M | |||||||
| Change in Working Capital | |||||||||||||||||||||||||||
| Change in Account PayablesChange Payables | -0.33M | -0.08M | -0.07M | 0.03M | 0.09M | 0.99M | -0.56M | 2.03M | -0.64M | 0.76M | -0.19M | 2.14M | -0.37M | ||||||||||||||
| Change in Accured ExpensesChange Accured Exp. | 0.02M | 0.06M | 0.01M | -0.14M | -0.01M | 0.01M | 0.03M | -0.03M | -0.01M | 0.07M | -0.03M | 0.00M | -0.03M | 0.05M | 0.01M | 0.01M | 0.00M | 0.12M | 0.07M | -0.22M | |||||||
| Cash from OperationsCash from Ops. | -0.60M | -0.89M | -2.26M | -1.95M | -0.53M | -1.55M | -2.17M | -1.56M | -0.97M | -1.80M | -2.15M | -1.78M | -1.05M | -2.58M | -1.85M | -1.83M | -2.23M | -2.67M | -3.17M | -4.70M | |||||||
| Financing Activities | |||||||||||||||||||||||||||
| Debt Issuance and Repayment | |||||||||||||||||||||||||||
| Long-Term Debt RepaymentsLT Debt Repayment | 5.51M | 2.02M | |||||||||||||||||||||||||
| Non-Current Debt | -5.51M | -2.02M | |||||||||||||||||||||||||
| Net Debt Issuances and RepaymentsNet Debt Issuance | -5.51M | -2.02M | |||||||||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||||||
| Common Stock IssuedStock Issued | 0.56M | 0.30M | 2.77M | 1.18M | 0.12M | 0.49M | 2.61M | 3.35M | 5.55M | 9.03M | |||||||||||||||||
| Shares Repurchased | 5.51M | 2.02M | |||||||||||||||||||||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 0.56M | -5.51M | -2.02M | 0.30M | 2.77M | 1.18M | 0.12M | 0.49M | 2.61M | 3.35M | 5.55M | 9.03M | |||||||||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 0.56M | -5.51M | -2.02M | 0.30M | 2.77M | 1.18M | 0.12M | 0.49M | 2.61M | 3.35M | 5.55M | 9.03M | |||||||||||||||
| Other financing activitiesOther financing | 0.07M | 0.07M | |||||||||||||||||||||||||
| Cash from Financing ActivitiesCash from Financing | 0.56M | -5.51M | -2.02M | 0.30M | 2.77M | 1.18M | 0.12M | 0.49M | 2.61M | 3.35M | 5.55M | 9.03M | |||||||||||||||
| Additional items | |||||||||||||||||||||||||||
| Change in Cash | -0.60M | -0.89M | -1.70M | -7.46M | -2.56M | -1.55M | -2.17M | -1.56M | -0.97M | -1.80M | -2.15M | -1.48M | 1.72M | -1.40M | -1.73M | -1.34M | 0.38M | 0.68M | 2.37M | 4.33M | |||||||
| Ending Cash Balance | 29.80M | 28.91M | 27.20M | 19.74M | 17.19M | 15.64M | 13.47M | 11.91M | 10.94M | 9.14M | 6.99M | 5.51M | 7.22M | 5.82M | 4.09M | 2.75M | 3.13M | 3.81M | 6.18M | 10.51M | |||||||
| Free Cash FlowFCF | -0.60M | -0.89M | -2.26M | -1.95M | -0.53M | -1.55M | -2.17M | -1.56M | -0.97M | -1.80M | -2.15M | -1.78M | -1.05M | -2.58M | -1.85M | -1.83M | -2.23M | -2.67M | -3.17M | -4.70M | |||||||
| Net Cash FlowNCF | -0.60M | -0.89M | -1.70M | -7.46M | -2.56M | -1.55M | -2.17M | -1.56M | -0.97M | -1.80M | -2.15M | -1.48M | 1.72M | -1.40M | -1.73M | -1.34M | 0.38M | 0.68M | 2.37M | 4.33M |
Pull Greenwich LifeSciences's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=GLSI&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "GLSI", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=GLSI&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();